Search results for "quinoline"

showing 10 items of 391 documents

Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization

2015

Imiquimod, a toll-like receptor 7 (TLR7) agonist, is an active pharmaceutical ingredient (API) established for the topical treatment of several dermal cancerous and precancerous skin lesions. Within this work, the immunostimulatory effect of imiquimod is further exploited in a transcutaneous immunization (TCI) approach based on a solid nanoemulsion (SN) formulation. SN contains a combination of imiquimod with the model peptide antigen SIINFEKL as a novel approach to omit needle and syringe and optimize dermal antigen administration. Excipients including sucrose fatty acid esters and the pharmaceutically acceptable oils MCT (middle chain triglycerides), avocado oil, jojoba wax and squalene a…

0301 basic medicineSkin NeoplasmsChemistry PharmaceuticalImmunologyAntineoplastic AgentsImiquimodImmunopotentiatorBiologyAdministration Cutaneous030226 pharmacology & pharmacyMice03 medical and health sciencesFreeze-dryingSqualenechemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineAdjuvants ImmunologicAntigenIn vivomedicineAnimalsHumansActive ingredientImiquimodChromatographyVaccinationPermeationNanostructuresMice Inbred C57BL030104 developmental biologychemistryLangerhans CellsImmunologyAminoquinolinesImmunizationOilsPrecancerous Conditionsmedicine.drugCellular Immunology
researchProduct

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.

2017

Abstract Background The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting. However, it does not accomplish memory formation or permanent defiance of tumors in a therapeutic set-up. As a distinct immunologic approach, CTLA-4 blockade augments systemic immune responses and has shown long-lasting effects in preclinical experiments as well as in clinical trials. Objective The study investigates the vaccination capacity of TCI in combination with the checkpoint inhibitor CTLA-4 in matter…

0301 basic medicineSkin NeoplasmsOvalbuminmedicine.medical_treatmentMelanoma Experimentalchemical and pharmacologic phenomenaDermatologyBiochemistryT-Lymphocytes RegulatoryEpitope03 medical and health sciencesMice0302 clinical medicineImmune systemAntineoplastic Agents ImmunologicalAdjuvants ImmunologicmedicineCytotoxic T cellAnimalsHumansCTLA-4 AntigenMolecular BiologyImiquimodMembrane Glycoproteinsbusiness.industryMelanomahemic and immune systemsDrug SynergismTLR7Immunotherapymedicine.diseaseFlow CytometryXenograft Model Antitumor AssaysPeptide FragmentsMice Inbred C57BLCTL*030104 developmental biologyToll-Like Receptor 7CTLA-4030220 oncology & carcinogenesisImmunologyAminoquinolinesImmunotherapybusinessImmunologic MemoryT-Lymphocytes CytotoxicJournal of dermatological science
researchProduct

Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection

2017

Abstract Background Transcutaneous immunization (TCI) is a novel vaccination strategy utilizing the skin associated lymphatic tissue to induce immune responses. TCI using a cytotoxic T lymphocyte (CTL) epitope and the Toll-like receptor 7 (TLR7) agonist imiquimod mounts strong CTL responses by activation and maturation of skin-derived dendritic cells (DCs) and their migration to lymph nodes. However, TCI based on the commercial formulation Aldara only induces transient CTL responses that needs further improvement for the induction of durable therapeutic immune responses. Objective Therefore we aimed to develop a novel imiquimod solid nanoemulsion (IMI-Sol) for TCI with superior vaccination …

0301 basic medicineSkin NeoplasmsT cellImiquimodDermatologyLymphocytic ChoriomeningitisAdministration CutaneousBiochemistryEpitopeMajor Histocompatibility ComplexEpitopesMice03 medical and health sciences0302 clinical medicineImmune systemCell MovementAnimalsHumansLymphocytic choriomeningitis virusMedicineCytotoxic T cellMolecular BiologySkinMice KnockoutImiquimodMembrane Glycoproteinsbusiness.industryVaccinationTLR7Flow CytometryMice Inbred C57BLDisease Models AnimalCTL*030104 developmental biologymedicine.anatomical_structureToll-Like Receptor 7Langerhans Cells030220 oncology & carcinogenesisMyeloid Differentiation Factor 88ImmunologyAminoquinolinesEmulsionsbusinessCD8Signal TransductionT-Lymphocytes Cytotoxicmedicine.drugJournal of Dermatological Science
researchProduct

Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins

2017

Viral diseases remain serious threats to public health because of the shortage of effective means of control. To combat the surge of viral diseases, new treatments are urgently needed. Here we show that small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), induced the premature death of cells infected with different RNA or DNA viruses, whereas, at the same concentrations, no toxicity was observed in mock-infected cells. Moreover, these compounds limited viral replication and spread. Surprisingly, Bcl-2i also induced the premature apoptosis of cells transfected with viral RNA or plasmid DNA but not of mock-transfected cells. These results suggest that Bcl-2i sensiti…

0301 basic medicinevirusesFAMILY INHIBITORSlcsh:QR1-502Virus Replicationlcsh:Microbiologychemistry.chemical_compoundTranscription (biology)SALIPHENYLHALAMIDEhost responseTRANSCRIPTIONprogrammed cell deathinnate immunity1183 Plant biology microbiology virologySulfonamidesAniline CompoundsapoptosisTransfection3. Good healthInfectious DiseasesProto-Oncogene Proteins c-bcl-2X-L INHIBITORVirus DiseasesvirustauditVirusesRNA ViralBiologyTransfectionta3111Antiviral AgentsArticleCell LineMicrobiology in the medical areaantiviral agent03 medical and health sciencesohjelmoitunut solukuolemaVirologyMikrobiologi inom det medicinska områdetHumansMetabolomicsBenzothiazolesInnate immune systemapoptosis; antiviral agent; innate immunity; host responseZIKA VIRUS-INFECTIONCHRONIC LYMPHOCYTIC-LEUKEMIAPOTENTta1183INFLUENZA-Ata1182RNAIsoquinolinesVirology030104 developmental biologyViral replicationchemistryCell cultureApoptosisCELLSREPLICATIONDNA Viral3111 BiomedicineDNA
researchProduct

CCDC 901286: Experimental Crystal Structure Determination

2013

Related Article: Anna Zakrzewska, Erkki Kolehmainen, Arto Valkonen, Esa Haapaniemi, Kari Rissanen, Lilianna Chęcińska, and Borys Ośmiałowski|2013|J.Phys.Chem.A|117|252|doi:10.1021/jp311072q

11-Difluoro-3-(4-methylphenyl)-1H-11lambda^5^1lambda^5^-[132]oxazaborinino[34-a]quinolineSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1569164: Experimental Crystal Structure Determination

2017

Related Article: Toms Rekis, Simone d’Agostino, Dario Braga, Fabrizia Grepioni|2017|Cryst.Growth Des.|17|6477|doi:10.1021/acs.cgd.7b01146

2-(1-azabicyclo[2.2.2]octan-3-yl)-6-(piperidin-1-yl)-1H-benzo[de]isoquinoline-13(2H)-dioneSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1569165: Experimental Crystal Structure Determination

2017

Related Article: Toms Rekis, Simone d’Agostino, Dario Braga, Fabrizia Grepioni|2017|Cryst.Growth Des.|17|6477|doi:10.1021/acs.cgd.7b01146

2-(1-azabicyclo[2.2.2]octan-3-yl)-6-(piperidin-1-yl)-1H-benzo[de]isoquinoline-13(2H)-dioneSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1569162: Experimental Crystal Structure Determination

2017

Related Article: Toms Rekis, Simone d’Agostino, Dario Braga, Fabrizia Grepioni|2017|Cryst.Growth Des.|17|6477|doi:10.1021/acs.cgd.7b01146

2-(1-azabicyclo[2.2.2]octan-3-yl)-6-(piperidin-1-yl)-1H-benzo[de]isoquinoline-13(2H)-dioneSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2070166: Experimental Crystal Structure Determination

2021

Related Article: Shrabani Saha, Sujoy Das, Olivia Sarkar, Ansuman Chattopadhyay, Kari Rissanen, Prithidipa Sahoo|2021|New J.Chem.|45|17095|doi:10.1039/D1NJ02661E

2-(9-ethyl-9H-carbazol-3-yl)-1H-benzo[de]isoquinoline-13(2H)-dioneSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 916245: Experimental Crystal Structure Determination

2013

Related Article: Santos Fustero, Ignacio Ibáñez, Pablo Barrio, Miguel A. Maestro, Silvia Catalán|2013|Org.Lett.|15|832|doi:10.1021/ol3035142

3-(4-Methoxyphenyl)-1-(trifluoromethyl)-1234-tetrahydroisoquinolineSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct